What's Happening?
OneOncology, a national platform supporting independent medical specialty practices, has been approved by the Centers for Medicare & Medicaid Services (CMS) as a Qualified Clinical Data Registry (QCDR) for 2026. This marks the second consecutive year
that OneOncology has received this designation, which allows it to collect and submit clinical data for healthcare providers participating in CMS's Quality Payment Program. The approval underscores OneOncology's commitment to meeting federal standards and improving oncology care through streamlined quality reporting. The organization has also developed a new oncology-specific quality measure, DPYD screening, approved for use in the Merit-based Incentive Payment System (MIPS) program. This measure helps identify patients at risk for severe side effects from certain chemotherapy drugs, allowing for personalized treatment.
Why It's Important?
The approval of OneOncology as a QCDR by CMS is significant for the healthcare industry, particularly in oncology. It facilitates improved data collection and reporting, which can enhance the quality of care provided to cancer patients. By aligning quality measures with real-world oncology workflows, OneOncology aims to reduce administrative burdens and improve performance in the MIPS program. The introduction of the DPYD screening measure is particularly important as it enhances patient safety by allowing for more personalized and safer chemotherapy treatments. This development could lead to better patient outcomes and reduced healthcare costs by minimizing adverse drug reactions.
What's Next?
OneOncology plans to continue integrating medical oncology, radiation oncology, and urology within its partner practices. The organization will leverage its expertise to help practices achieve quality measures and deliver high-quality specialty care. As the healthcare landscape evolves, OneOncology's role in supporting independent practices and improving patient access to care will be crucial. The ongoing development and implementation of new quality measures will likely continue, ensuring that practices remain compliant with updated national guidelines and standards.
